Overview

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are receiving erythropoietic agents, such as Procrit® and Aranesp®.

Phase:

Phase 4

Details

Lead Sponsor:

Watson Pharmaceuticals

Treatments:

Ferric Compounds
Ferric gluconate
Iron